

Summary Document for Interim Clinical Considerations

for Use of COVID-19 Vaccines Currently Authorized in the United States



	Pfizer-BioNTech	Moderna	Janssen
Vaccine type	mRNA	mRNA	Replication-incompetent adenovirus type 26 vector
Authorized age groups	≥12 years	≥18 years	≥18 years
Dose	30 µg	100 µg	5×10 ¹⁰ viral particles
Dose volume	0.3 ml	0.5 ml	0.5 ml
Number of doses in series	2*	2*	1
Interval between doses	3 weeks (21 days)	1 month (28 days)	N/A

All currently authorized COVID-19 vaccines

Interchangeability of vaccines	<ul style="list-style-type: none"> Vaccines are not interchangeable. However, in exceptional situations, such as a contraindication to a second dose of mRNA vaccine, interchangeability may be allowed.[†]
Interval between COVID-19 and other (non-COVID-19) vaccines	<ul style="list-style-type: none"> COVID-19 vaccine and other vaccines may be administered on the same day, as well as any interval without respect to timing. When deciding whether to administer COVID-19 vaccine and other vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable diseases (e.g., during an outbreak), and the reactogenicity profile of the vaccines.
Persons with prior or current COVID-19	<ul style="list-style-type: none"> COVID-19 vaccines can be given safely to people with prior SARS-CoV-2 infection Defer vaccination until person has recovered from the acute illness and criteria have been met for them to discontinue isolation
Women aged <50 years	<ul style="list-style-type: none"> Can receive any FDA-authorized vaccine but should be informed of risk of thrombosis with thrombocytopenia syndrome (TTS) after receipt of Janssen (Johnson & Johnson) COVID-19 Vaccine and the availability of other COVID-19 vaccine options
Persons who received monoclonal antibodies or convalescent plasma for COVID-19 treatment	<ul style="list-style-type: none"> Defer vaccination for at least 90 days
Persons with a known SARS-CoV-2 exposure	<ul style="list-style-type: none"> Persons in community or outpatient setting should defer vaccination until quarantine period has ended Residents or patients in congregate settings may be vaccinated if they do not have symptoms consistent with COVID-19
History of heparin-induced thrombocytopenia (HIT)	<ul style="list-style-type: none"> If within 90 days of illness, offer an mRNA vaccine, after 90 days vaccinate with any FDA-authorized COVID-19 vaccine
Persons with underlying conditions	<ul style="list-style-type: none"> May receive COVID-19 vaccine
Persons with moderate to severe immune compromise	<ul style="list-style-type: none"> Can receive any FDA-authorized COVID-19 vaccine <ul style="list-style-type: none"> 1 dose Janssen COVID-19 Vaccine; currently no recommendation for an additional dose, or 2-doses of an mRNA COVID-19 vaccine; consider an additional dose at least 28 days after completion of the primary 2-dose series
Persons with a history of Guillain-Barré Syndrome	<ul style="list-style-type: none"> Can receive any FDA-authorized COVID-19 vaccine, however, discuss the availability of mRNA vaccines to offer protection against COVID-19
Pregnant or breastfeeding people or people trying to get pregnant	<ul style="list-style-type: none"> Are recommended to receive a COVID-19 vaccine, inform of risk of TTS after receipt of Janssen (Johnson & Johnson) COVID-19 Vaccine and the availability of other options
Adolescents	<ul style="list-style-type: none"> Adolescents aged 12-17 are ONLY eligible for Pfizer-BioNTech COVID-19 Vaccine Adolescents aged 18 years and older are eligible for all COVID-19 vaccines
Persons vaccinated outside the United States	<ul style="list-style-type: none"> Received all recommended doses of an FDA-authorized COVID-19 vaccine, do not need additional doses Received a non FDA-authorized vaccine <ul style="list-style-type: none"> If vaccine is listed for emergency use by the World Health Organization (WHO) and received all recommended doses, do not need any additional doses with an FDA-authorized vaccine If vaccine is listed for emergency use by WHO, but has not received all recommended doses, may be offered a complete FDA-authorized series If vaccine is not listed for emergency use by WHO, may be offered a complete FDA-authorized COVID-19 vaccine series
Contraindications	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to component of the COVID-19 vaccine Immediate (within 4 hours of exposure) allergic reaction of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine
Precaution	<ul style="list-style-type: none"> Immediate allergic reaction to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous immunotherapy for allergies, i.e., “allergy shots”])
Post-vaccination observation periods	<ul style="list-style-type: none"> 30 minutes: persons with a precaution to vaccination (i.e., history of an immediate allergic reaction of any severity to a vaccine or injectable therapy) and persons with a history of anaphylaxis due to any cause 15 minutes: all other persons
SARS-CoV-2 antibody testing	<ul style="list-style-type: none"> Antibody testing not recommended for vaccine decision-making or to assess immunity following vaccination

* Consider an additional dose at least 28 days after the initial 2-dose primary series for people with moderate to severe immune compromise.

†Although CDC provides considerations for a [mixed series in exceptional circumstances](#), this is still considered an administration error that requires VAERS reporting